Durvalumab (D) and tremelimumab (T) as first-line treatment (tx) for participants (pts) with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis: Primary efficacy and safety results from the phase IIIB SIERRA study

  • Rimassa, L.; 
  • Kudo, M.; 
  • Sangro, B.; 
  • Kelley, R. k.; 
  • Kim, J. h.; 
  • ... Hong, J. y.; 
  • 외 13명
Citations

WEB OF SCIENCE

0
제목
Durvalumab (D) and tremelimumab (T) as first-line treatment (tx) for participants (pts) with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis: Primary efficacy and safety results from the phase IIIB SIERRA study
저자
Rimassa, L.; Kudo, M.; Sangro, B.; Kelley, R. k.; Kim, J. h.; Van Binh, P.; Hong, J. y.; Waldschmidt, D. t.; Marino, D.; Gerolami, R.; Burgoyne, A.; Masi, G.; Walsh, R. j.; Marquardt, J. u.; Emeribe, U.; Balaji, K.; Sun, P.; Baur, B.; Chan, S. l.
DOI
10.1016/j.annonc.2026.05.259
발행일
2026-07
유형
Meeting Abstract
저널명
Annals of Oncology
권
37
페이지
S82 ~ S83